Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectivesFootnote1

1. Data included in this manuscript were presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, 24–27 July 2005, in Rio de Janeiro, Brazil (poster WePe12.2C12).

References

• American Foundation for AIDS Research (amfAR) . 2005 , April ). Survey results . Presented at the 17th National HIV/AIDS Update Conference, Oakland, CA. Retrieved September 2, 2008, from http://www.amfar.org/cgi-bin/iowa/programs/researchc/record.html?record=232
   Google Scholar
• Arasteh , K. Lazzarin , A. , Clotet , B. , Lalezari , J. , Cooper , D. , Henry , K. , et al. . 2004 . TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen . XV International AIDS Conference, July, Bangkok; Abstract MoOrB1058 .
   Google Scholar
• Campbell , C. and McGauley , G. 2005 . Doctor-patient relationships in chronic illness: Insights from forensic psychiatry . British Medical Journal , 330 : 667 – 670 .
   PubMed Web of Science ®Google Scholar
• Cohen , C.J. , Hellinger , J. , Johnson , M. , Staszewski , S. , Wintfeld , N. Patel , K. 2003 . Patient acceptance of self-injected enfuvirtide at 8- and 24-weeks . HIV Clinical Trials , 4 : 347 – 357 .
   PubMed Web of Science ®Google Scholar
• Eron , J. , Delfraissy , J.F. , Kuritzkes , D. , Stellbrink , H.-J. , Cohenn , C. , DeMasi , R. , et al. . 2003 . Safety of enfuvirtide through 48 weeks of therapy in the TORO trials . 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September. Chicago; Abstract H-836 .
   Google Scholar
• Greenberg , M.L. , Sista , P. , & Miralles , G. 2002 Enfuvirtide (T-20) and T-1249 resistance: Observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals (ARVs) and a Phase I/II doseranging monotherapy trial of T-1249 . XI International HIV Drug Resistance Workshop, July. Seville .
   Google Scholar
• Horne , R. , Coombes , I. , Davies , G. , Hankins , M. and Vincent , R. 1999 . Barriers to optimum management of heart failure by general practitioners . British Journal of General Practice , 49 : 353 – 357 .
   PubMed Web of Science ®Google Scholar
• Katlama , C. , Arastéh , K. , Clotet , B. , Cooper , D. , Henry , K. , Lalezari , J. , et al. . 2003 . Enfuvirtide TORO studies: 48-week results confirm 24-week findings . 2nd International AIDS Society Meeting, July, Paris; Abstract LB2 .
   Google Scholar
• Lalezari , J.P. , Henry , K. , O'Hearn , M. , Montaner , J.S. , Piliero , P.J. Trottier , B. 2003 . Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America . New England Journal of Medicine , 348 : 2175 – 2185 .
   PubMed Web of Science ®Google Scholar
• Lazzarin , A. , Clotet , B. , Cooper , D. , Reynes , J. , Arastéh , K. Nelson , M. 2003 . Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia . New England Journal of Medicine , 348 : 2186 – 2195 .
   PubMed Web of Science ®Google Scholar
• Montaner , J. , et al. . 2004 . A treatment staging proposal derived from a post-hoc analysis of the 48-week results from the TORO studies . 15th International AIDS Conference, July, Bangkok; Abstract TuPEB4483 .
   Google Scholar
• Perry , N. , et al. . 2005 . T20 Use in the UK: Is it Optimal? 11th Annual Conference of the British HIV Association [BHIVA] with the British Association for Sexual Health and HIV [BASHH]. Dublin, Ireland, 21–23 April; Abstract P31
   Google Scholar
• Trottier , B. , Arastéh , K. , Henry , K. , Katlama , C. , Lazarin , A. , Montaner , J. , et al. . 2004 Durability of response of enfuvirtide through 48 weeks in the TORO trials . 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September. Chicago; Abstract H-835 .
   Google Scholar